Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -8.88 is 146% below its 4-year average of 19.33, near the low end of its 4-year range (-9.04–116.58).
116.51% below its 12-month average of 53.77.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.34.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 13 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:32:30.219Z. Historical observations retain their original dates. Historical series through 2025-08-13.
EARNINGS PER SHARE (EPS)
-8.88
EARNINGS PER SHARE (EPS) AVG TTM
53.77
EARNINGS PER SHARE (EPS) AVG 3Y
24.70
EARNINGS PER SHARE (EPS) AVG 5Y
19.33
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-116.51%
CURRENT VS 3Y AVG
-135.95%
CURRENT VS 5Y AVG
-145.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inhibrx Biosciences Inc.
Market Cap
$1.42B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
Market Cap
$1.41B
Earnings Per Share (EPS)
0.90
TTM Avg
0.79
3Y Avg
0.56
5Y Avg
0.48
Market Cap
$1.44B
Earnings Per Share (EPS)
N/A
TTM Avg
-1.26
3Y Avg
-1.26
5Y Avg
-1.26
Market Cap
$1.44B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.38B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.33
3Y Avg
-2.33
5Y Avg
-2.33
Market Cap
$1.46B
Earnings Per Share (EPS)
1.71
TTM Avg
0.68
3Y Avg
0.58
5Y Avg
0.72
Market Cap
$1.47B
Earnings Per Share (EPS)
-2.74
TTM Avg
-3.05
3Y Avg
-2.66
5Y Avg
-2.66
Market Cap
$1.48B
Earnings Per Share (EPS)
-0.44
TTM Avg
-0.04
3Y Avg
-0.09
5Y Avg
-0.12
Market Cap
$1.36B
Earnings Per Share (EPS)
1.72
TTM Avg
-1.38
3Y Avg
-1.54
5Y Avg
-1.77
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.42B | -8.88 | 53.77 | 24.70 | 19.33 |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 0.90 | 0.79 | 0.56 | 0.48 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.44B | N/A | -1.26 | -1.26 | -1.26 |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 5.37 | -2.79 | -4.06 | -3.18 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | N/A | -2.33 | -2.33 | -2.33 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 1.71 | 0.68 | 0.58 | 0.72 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | -2.74 | -3.05 | -2.66 | -2.66 |
| Certara, Inc. (CERT)vs › | $1.48B | -0.44 | -0.04 | -0.09 | -0.12 |
| Omeros Corporation (OMER)vs › | $1.36B | 1.72 | -1.38 | -1.54 | -1.77 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.49B | N/A | N/A | N/A | N/A |
Trailing EPS (TTM)
$-8.88
Forward EPS (Est.)
$-9.52
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -9.04 |
| 2024-12-31 | 116.58 |
| 2023-12-31 | -5.12 |
| 2022-12-31 | -3.62 |
| 2021-12-31 | -2.15 |
| 2019-12-31 | -1.41 |
| 2018-12-31 | -1.15 |
| 2017-12-31 | -0.68 |
| 2016-12-31 | -0.23 |
